64E-5.626. Use of Radiopharmaceuticals for Uptake, Dilution, or Excretion Studies

A licensee is allowed to use any unsealed radioactive material in a radiopharmaceutical for a diagnostic use involving measurements of uptake, dilution, or excretion for medical use under the following conditions: (1) When a written directive is not required by subsection 64E-5.607(3), F.A.C., the licensee must satisfy the following: (a) Radioactive material is obtained from a manufacturer or pharmacy licensed as specified in subsection 64E-5.210(10), F.A.C., or in equivalent NRC or agreement state regulations, or (b) Radioactive material is obtained from and prepared by a NRC or agreement state licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol, or a Notice of Claimed Investigational Exemption for a New Drug (IND) protocol accepted by U.S. Food and Drug Administration (FDA), or (c) Radioactive material is prepared by the licensee for use in research in accordance with a Radioactive Drug Research Committee-approved application, or an IND protocol accepted by FDA, or (d) Radioactive material is prepared by: 1. An authorized nuclear pharmacist, 2. Except for sodium iodide I-131 in quantities greater than 30 microcuries (1.11 MBq), a physician who is an authorized user and meets the training requirements specified in Rule 64E-5.650 or 64E-5.660, and sub-subparagraph 64E-5.650(3)(a)2.g., F.A.C., or 3. An individual under the supervision of a physician who is an authorized user under subparagraph 64E-5.626(1)(d)2., F.A.C., and as specified in paragraphs 64E-5.601(3)(a) and (b), 64E-5.607(3)(e), or subsection 64E-5.608(1), F.A.C., or (e) The authorized user must satisfy the training and experience specified in Rule 64E-5.649 or 64E-5.657, F.A.C. (2) When a written directive is required by subsection 64E-5.607(3), F.A.C., the licensee must satisfy the following: (a) Radioactive material is obtained from a manufacturer or pharmacy licensed as specified in subsection 64E-5.210(10), F.A.C., or in equivalent NRC or agreement state regulations, or (b) Radioactive material is obtained from and prepared by an NRC or agreement state licensee for use in research in accordance with a Radioactive Drug Research Committee-approved protocol or an IND protocol accepted by FDA, or (c) Radioactive material is prepared by the licensee for use in research in accordance with a Radioactive Drug Research Committee-approved application, or an IND protocol accepted by FDA, or (d) Radioactive material is prepared by: 1. An authorized nuclear pharmacist, 2. A physician who is an authorized user and meets the training requirements specified in Rule 64E-5.650 or 64E-5.660, F.A.C., or 3. An individual under the supervision of a physician who is an authorized user under subparagraph 64E-5.626(1)(d)2., F.A.C., and as specified in paragraphs 64E-5.601(3)(a) and (b), 64E-5.607(3)(e) or subsection 64E-5.608(1), F.A.C. (e) The authorized user must satisfy the applicable training and experience specified in Rule 64E-5.657, 64E-5.660, 64E-5.661, 64E-5.662 or 64E-5.663, F.A.C.